Research programme: Antibody drug nanoparticle albumin bound immune complex therapeutics - Sorrento Therapeutics
Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Sorrento Therapeutics
- Developer ADNAB; Sorrento Therapeutics
- Class Albumins; Antineoplastics; Antivirals; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
- No development reported COVID 2019 infections; Haematological malignancies; Solid tumours
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)
- 28 Oct 2024 No recent reports of development identified for research development in Haematological-malignancies in USA (Parenteral)
- 28 Oct 2024 No recent reports of development identified for research development in Solid-tumours in USA (Parenteral)